argenx to Present at Upcoming Investor Conferences

ARGX 11.26.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-12-03
Name of Upcoming Event:Citi’s 2024 Global Healthcare Conference
Date of Upcoming Event:2024-12-04
Name of Upcoming Event:7th Annual Evercore I&I HealthCONx Conference
Date of Upcoming Event:2024-12-05
Name of Upcoming Event:Piper Sandler’s 35th Annual Healthcare Conference
Full Press ReleaseSEC FilingsOur ARGX Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - argenx Highlights 2025 Strategic Priorities
  • 01.06.2025 - argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
  • 12.27.2024 - argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Recent Filings

  • 01.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 12.27.2024 - EX-99.1 EX-99.1
  • 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors

November 26, 2024Amsterdam, the Netherlands– argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December.

  • Citi’s 2024 Global Healthcare Conference.Fireside chat onTuesday, December 3at1:45 p.m. ETinMiami, FL.
  • 7thAnnualEvercore I&I HealthCONx Conference.Fireside chat onWednesday, December 4at1:45 p.m. ETinCoral Gables, FL.
  • Piper Sandler’s 35thAnnual Healthcare Conference.Fireside chat onThursday, December 5at9:00 a.m. ETinNew York, NY.

Additional information regarding these events will be available on the Investors section of the argenx website atargenx.com/investors.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in theU.S.,Japan,Israel, the EU, theUK,ChinaandCanada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visitwww.argenx.comand follow us onLinkedIn,X/Twitter,Instagram,Facebook, andYouTube.

For further information, please contact:

Media:

Ben Petokbpetok@argenx.com

Investors:

Alexandra Roy(US)aroy@argenx.com

Lynn Elton(EU)lelton@argenx.com

Primary Logo

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com